ArticleEuropean journal of immunology2021
Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.
Article in European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 77 citations in OpenAlex.
- Analytical validation of a multiplexed peptide microarray for multi-antigen Epstein-Barr virus serological profiling across diverse clinical specimens.Frontiers in immunology · 2026Article
- Article
- Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.PloS one · 2025Article
- Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein.International journal of molecular sciences · 2024Article
- A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- SARS-CoV-2 Spike protein peptides displayed in the Pyrococcus furiosus RAD system preserve epitopes antigenicity, immunogenicity, and virus-neutralizing activity of antibodies.Scientific reports · 2023Article
- SARS-CoV-2 Gut-Targeted Epitopes: Sequence Similarity and Cross-Reactivity Join Together for Molecular Mimicry.Biomedicines · 2023Article
- Serodominant SARS-CoV-2 Nucleocapsid Peptides Map to Unstructured Protein Regions.Microbiology spectrum · 2023Article
- Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.Journal of translational medicine · 2023Article
- Peptide microarray analysis of in-silico predicted B-cell epitopes in SARS-CoV-2 sero-positive healthcare workers in Bulawayo, Zimbabwe.Acta tropica · 2023Article
- Exploring the Immunodominant Epitopes of SARS-CoV-2 Nucleocapsid Protein as Exposure Biomarker.Cureus · 2023Article
- Linear epitope mapping of the humoral response against SARS-CoV-2 in two independent African cohorts.Scientific reports · 2023Article
- Article
- Article
- Characterization and application of a series of monoclonal antibodies against SARS-CoV-2 nucleocapsid protein.Journal of medical virology · 2023Article
- A linear B-cell epitope close to the furin cleavage site within the S1 domain of SARS-CoV-2 Spike protein discriminates the humoral immune response of nucleic acid- and protein-based vaccine cohorts.Frontiers in immunology · 2023Article
- Applications of Peptide Microarrays in Autoantibody, Infection, and Cancer Detection.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Fast Protocols for Characterizing Antibody-Peptide Binding.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is not fully understood yet but is a crucial factor of immune protection. The possibility of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) would have important implications for immune protection but also for the development of specific diagnostic ELISA tests. Using peptide microarrays, n = 24 patient samples and n = 12 control samples were screened for antibodies against the entire SARS-CoV-2 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a (AP3A) of the HCoV strains SARS, MERS, OC43, and 229E. While widespread cross-reactivity was revealed across several immunodominant regions of S and N, IgG binding to several SARS-CoV-2-derived peptides provided statistically significant discrimination between COVID-19 patients and controls. Selected target peptides may serve as capture antigens for future, highly COVID-19-specific diagnostic antibody tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.